Web13 aug. 2024 · Palliative radiotherapy (RT) represents an important treatment opportunity for improving the quality of life in metastatic non-small cell lung cancer (NSCLC) patients through the management of symptoms within the course of the illness. Web1 dag geleden · Roundtable Discussion: Bodor Reviews Benefits, Challenges of Immunotherapy for Squamous NSCLC. During a Targeted Oncology™ Case-Based Roundtable™ event, J. Nicholas Bodor, MD, PhD, MPH, discussed the CheckMate 9LA regimen of nivolumab and ipilimumab plus chemotherapy for patients with advanced …
2024 AACR 前瞻 重磅前沿进展一文速览 单抗 报告人 实体瘤 with her2 nsclc…
Web22 mrt. 2024 · In May 2024, the U.S. Food and Drug Administration (FDA) approved the first oral targeted therapy for patients with non–small cell lung cancer (NSCLC) whose tumors harbor a specific KRAS mutation called KRAS p.G12C. 1 Currently, sotorasib is indicated 2 for patients with locally advanced or metastatic NSCLC after disease progression on a … Web14 feb. 2024 · Resectable non-small cell lung cancer (NSCLC) is currently treated with cisplatin-based adjuvant chemotherapy following surgical resection. Despite treatment with curative intent, there are high rates of disease recurrence with distant metastases, resulting in a 5-year mortality of 20-60%. change to indonesian language
Journal Club ESMO
Web25 nov. 2024 · Surgery. Surgery for NSCLC has proven to be effective, with National Cancer Registration and Analysis Service (NCRAS) data showing that 45% of people with NSCLC were still alive 5 years post-surgery. Five-year survival rates for people with NSCLC who do not have surgery was 3%. Over the last 10 years, surgery rates in NSCLC have doubled, … Web16 nov. 2024 · A void in the treatment landscape exists for patients with advanced non–small cell lung cancer (NSCLC) who receive 1 to 2 lines of prior therapy as the average overall survival (OS) is less than ... WebOncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. This ESMO Clinical Practice Guideline provides key recommendations and algorithms for managing oncogene-addicted mNSCLC. The guideline covers diagnosis, staging, risk assessment, treatment and disease monitoring. harecroft wilsden